Free Newsletter
Judge throws out RICO class action
Do RICO claims against drugmakers have a real chance? The answer appears to be yes and no. A federal judge in Florida threw out a case pitting several union health benefit funds against AstraZeneca over Seroquel. The funds claimed that they were hoodwinked by an off-label marketing campaign that misrepresented Seroquel's safety and efficacy. And they sued the drugmaker under the Racketeering Influenced Corrupt Organizations act.
The Florida judge, Anne Conway, said the RICO claims wouldn't stand as a class action because doctors determining whether any misrepresentations about Seroquel influenced prescribing behavior would require questioning the physicians one by one--and patient by patient. That ruling conflicts with another in a RICO case involving Eli Lilly; Judge Jack Weinstein allowed the class-action RICO claims to proceed.
One expert told Pharmalot that Conway's ruling should cheer drugmakers fearing RICO-based class actions. "These two decisions are both at the trial court level, so they're less significant than appellate decisions would be," said Mark Herrman, an attorney at Jones Day who defends drugmakers. "But they reflect a high-stakes game, because they speak to whether insurance companies can bring RICO class actions by saying that drug companies misrepresented the benefits of their drugs, increasing the insurers' payments."
- see the Pharmalot article
Related Articles:
AZ bids for yet another Seroquel use
AZ stock leaps on Seroquel hearing news
Seroquel researcher got cash from AZ
AZ takes steps to shore up Seroquel
AZ's Seroquel receives additional approval
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: